Controlled IL-12 Expression

Client: Ziopharm


Ziopharm’s Controlled IL-12 platform can help provide therapy for cold tumors that exhibit little or no immune system activity by turning them hot. IL-12 is a powerful cytokine and master regulator of the immune system. Ad-RTS-hIL-12 plus veledimex is a gene therapy with an adenoviral vector providing the vehicle engineered to express IL-12 under the control of the RheoSwitch Therapeutic System®. This IL-12 monotherapy is used in combination with checkpoint inhibitors to treat glioblastoma, with therapeutic potential for breast cancer and melanoma.

Bronze Award

Digital Health Awards

See also


Tumor Immunotherapy



Our pride and reputation are in everything we deliver.

Visit our process page to see how our award winning animations get created.